Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FL
Horizon Flexible Income ETF
FLXN
Volume
5.52K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
FL
FLXN
FL
Horizon Flexible Income ETF
FLXN
News
·
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
AUM
N/A
Volume
5.52K
Yield
9.48%
Chart
Earnings
News
About
Dividends
Insider
Filings
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.
Zacks Investment Research · Nov 3, 2021
Earnings Preview: Flexion Therapeutics (FLXN) Q3 Earnings Expected to Decline
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · Oct 27, 2021
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?
On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.
Zacks Investment Research · Oct 25, 2021
Slow Start to Busy Week of Inflation Data and Earnings
Slow Start to Busy Week of Inflation Data and Earnings
Zacks Investment Research · Oct 12, 2021
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ: AZN) (announced positive data for COVID-19 antibody treatment) Bicycle Therapeutics plc (NASDAQ: BCYC) Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) Itamar Medical Ltd. (NASDAQ: ITMR) Legend Biotech Corporation (NASDAQ: LEGN) Merus N.V. (NASDAQ: MRUS) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 12) Absci Corporation (NASDAQ: ABSI) Acutus Medical, Inc. (NASDAQ: AFIB) Addex Therapeutics Ltd (NASDAQ: ADXN) ADMA Biologics, Inc. (NASDAQ: ADMA) Allogene Therapeutics, Inc. (NASDAQ: ALLO) Ambrx Biopharma Inc. (NYSE: AMAM) Amgen Inc. (NASDAQ: AMGN) Applied Genetic Technologies Corporation (NASDAQ: AGTC) Applied Molecular Transport Inc. (NASDAQ: AMTI) Athenex, Inc. (NASDAQ: ATNX) (provided positive update from Type A meeting with the Food and Drug Administration regarding approval of breast cancer drug) Axcella Health Inc. (NASDAQ: AXLA) Aytu Biopharma, Inc. (NASDAQ: AYTU) BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) BioSig Technologies, Inc. (NASDAQ: BSGM) BioVie Inc. (NASDAQ: BIVI) Cardiovascular Systems, Inc. (NASDAQ: CSII) Centessa Pharmaceuticals Limited (NASDAQ: CNTA) Century Therapeutics, Inc. (NASDAQ: IPSC) Chemomab Therapeutics Ltd. (NASDAQ: CMMB) DICE Therapeutics, Inc. (NASDAQ: DICE) Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) Eliem Therapeutics, Inc. (NASDAQ: ELYM) Exscientia Holdings Limited (NASDAQ: EXAI) (IPOed Oct. 1) Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) Frequency Therapeutics, Inc. (NASDAQ: FREQ) Gain Therapeutics, Inc. (NASDAQ: GANX) GBS Inc. (NASDAQ: GBS) Glaukos Corporation (NYSE: GKOS) Guardion Health Sciences, Inc. (NASDAQ: GHSI) Harpoon Therapeutics, Inc. (NASDAQ: HARP) HOOKIPA Pharma Inc. (NASDAQ: HOOK) IN8bio, Inc. (NASDAQ: INAB) IsoPlexis Corporation (NASDAQ: ISO) (IPOed Friday) Jasper Therapeutics, Inc. (NASDAQ: JSPR) Kala Pharmaceuticals, Inc. (NASDAQ: KALA) Kamada Ltd. (NASDAQ: KMDA) Kiromic BioPharma, Inc. (NASDAQ: KRBP) (announced strategic collaboration to advance its first allogeneic CAR-T clinical trial candidate, Alexis ISO-1) Kronos Bio, Inc. (NASDAQ: KRON) Mustang Bio, Inc. (NASDAQ: MBIO) Nautilus Biotechnology, Inc. (NASDAQ: NAUT) NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Omeros Corporation (NASDAQ: OMER) OncoSec Medical Incorporated (NASDAQ: ONCS) Orchard Therapeutics plc (NASDAQ: ORTX) Pacira BioSciences, Inc. (NASDAQ: PCRX) - announced deal to acquire Flexion Therapeutics, Inc. (NASDAQ: FLXN) to expand non-opioid pain drug portfolio Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) Pharming Group N.V. (NASDAQ: PHAR) Poseida Therapeutics, Inc. (NASDAQ: PSTX) Prelude Therapeutics Incorporated (NASDAQ: PRLD) Pulmatrix, Inc. (NASDAQ: PULM) Pyxis Oncology, Inc. (NASDAQ: PYXS) (IPOed Friday) Rain Therapeutics Inc. (NASDAQ: RAIN) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) Repare Therapeutics Inc. (NASDAQ: RPTX) Rhythm Pharmaceuticals, Inc. (NASDAQ:
Benzinga · Oct 12, 2021
Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management
-- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --
GlobeNewswire Inc. · Oct 11, 2021
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewswire Inc. · Oct 1, 2021
Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.
GlobeNewswire Inc. · Sep 8, 2021
Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference
BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021.
GlobeNewswire Inc. · Sep 3, 2021
Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee
BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee.1
GlobeNewswire Inc. · Sep 2, 2021
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
FL
FLXN
Horizon Flexible Income ETF
Buy
Sell
Market
Limit
Soon
FLXN
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any FLXN yet.
Related Tickers
Earnings
Dividends
Last · Sep 25
Monthly
Amount
$0.19
Yield
10.47%
Annual
$2.52